Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: A qualitative analysis

Melanoma Research

Volumn 12, Issue 5, 2002, Pages 491-498

  Palermo, B ^a   Campanelli, R ^a   Garbelli, S ^a   Mantovani, S ^a   Della Cuna, G Robustelli ^a   Necker, A ^a   Manganoni, A M ^a   Carella, G ^a   Rivoltini, L ^a   Lantelme, E ^a   Giachino, C ^a  

^a IRCCS   (Italy)

Author keywords

Cancer vaccine; Cytotoxic T lymphocyte; HLA tetramer; Melan A MART 1; Melanoma

Indexed keywords

EPITOPE; HLA ANTIGEN; MELAN A; PEPTIDE DERIVATIVE; PROTEIN A27L; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; PEPTIDE; TUMOR PROTEIN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CASE REPORT; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; ANTIBODY AFFINITY; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN BINDING;

ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; MELANOMA; NEOPLASM PROTEINS; PEPTIDES; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036752157     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200209000-00011     Document Type: Article

References (32)

1. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
2. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc Natl Acad Sci USA 1994; 91: 3515-3519.
3. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-352.
4. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 1998; 75: 451-458.
5. Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Lienard D, et al. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J Immunol 1998; 161: 6956-6962.
6. Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999; 82: 669-677.
7. van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, et al. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 1996; 26: 1683-1689.
8. Valmori D, Fonteneau J-F, Lizana CM, Gervois N, Lienard D, Rimoldi D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160: 1750-1758.
9. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586-5592.
10. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157: 2539-2548.
11. Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, et al. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy. Cancer Res 1999; 59: 301-307.
12. Slansky EJ, Rattis MF, Boyd FL, Fahmy T, Jaffee ME, Schneck PJ, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13: 529-538.
13. Valmori D, Pittet MJ, Rimoldi D, Lienard D, Dunbar R, Cerundolo V, et al. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res 1999; 59: 2167-2173.
14. Bocchia M, Bronte V, Colombo MP, De Vincentis A, Di Nicola M, Forni G, et al. Antitumor vaccination: Where we stand. Haematologica 2000; 85: 1172-1206.
15. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. J Immunol 2000; 164: 1125-1131.
16. Palermo B, Campanelli R, Mantovani S, Lantelme E, Manganoni AM, Carella G, et al. Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. Eur J Immunol 2001; 31: 412-420.
17. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, et al. Specific CTL responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of MHC/peptide tetramers: Role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001; 117: 326-332.
18. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96.
19. Ogg GS, McMicheal AJ. HLA-peptide tetrameric complexes. Curr Opin Immunol 1998; 10: 393-396.
20. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93: 4102-4107.
21. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162: 989-994.
22. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol 2001; 13: 141-146.
23. Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999; 162: 1749-1755.
24. Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM. Dose-dependent T cell tolerance to an immunodominant self peptide. Eur J Immunol 1994; 24: 1743-1749.
25. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995; 3: 407-415.
26. Van den Eynde BJ, Morel S. Differential processing of class-1-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 2001; 13: 147-153.
27. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 1999; 29: 4037-4042.
28. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486-1490.
29. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996; 274: 1363-1366.
30. Chen Q, Jackson H, Cebon J, Gibbs P, Davis ID, Trapani JA. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: Differential immunogenicity of Melan-A27-35 and Melan-A26-35. Melanoma Res 2000; 10: 16-25.
31. Derby MA, Wang J, Margulies DH, Berzofsky JA. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int Immunol 2000; 13: 817-824.
32. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopaietic progenitor cells. Int J Cancer 2000; 86: 385-392.